Outlook Therapeutics, Inc. (OTLK)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 09-30. Amounts in USD.

Revenue Quarterly

0 2M 4M 6M Q2 '15: 494.9K Q3 '15: 1.3M Q4 '15: 494.9K Q1 '16: 994.9K Q2 '16: 994.9K Q3 '16: 494.9K Q4 '16: 494.9K Q1 '17: 303.1K Q2 '17: 303.1K Q3 '17: 303.1K Q4 '17: 2.9M Q1 '18: 771.9K Q2 '18: 771.9K Q3 '18: 771.9K Q4 '18: 771.9K Q1 '19: 1.1M Q2 '19: 641.1K Q3 '19: 583.8K Q4 '19: 5.9M Q3 '25: 1.5M Q3 '15 Q2 '16 Q1 '17 Q4 '17 Q3 '18 Q2 '19 Q3 '25

Gross Profit Quarterly

-1.5M -1M -500K 0 500K 1M 1.5M Q3 '25: 1.1M Q1 '26: -1.2M Q2 '26: -21.9K Q3 '26: -8.3K Q3 '25 Q1 '26 Q2 '26 Q3 '26

Operating Income Quarterly

-24M -16M -8M 0 8M 16M 24M Q4 '21: -13.4M Q1 '22: -13.1M Q2 '22: -18.9M Q3 '22: -17M Q4 '22: -14M Q1 '23: -15.7M Q2 '23: -6.8M Q3 '23: -18.1M Q4 '23: -12.5M Q1 '24: -10.3M Q2 '24: -18.9M Q3 '24: -19.6M Q4 '24: -22.9M Q1 '25: -21.6M Q2 '25: -12.4M Q3 '25: -15.7M Q4 '25: -17.3M Q1 '26: -13.5M Q2 '26: -14M Q3 '26: -10.8M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Net Income Quarterly

-120M -80M -40M 0 40M 80M 120M Q4 '21: -13.4M Q1 '22: -14.5M Q2 '22: -19.7M Q3 '22: -17.5M Q4 '22: -14.3M Q1 '23: -18.7M Q2 '23: -6.7M Q3 '23: -20.7M Q4 '23: -13M Q1 '24: -11.2M Q2 '24: -114.3M Q3 '24: 44.4M Q4 '24: 5.7M Q1 '25: 17.4M Q2 '25: -46.4M Q3 '25: -20.2M Q4 '25: -13.3M Q1 '26: -23.1M Q2 '26: -4.5M Q3 '26: -20.3M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Cost of Revenue Quarterly

0 350K 700K 1.1M Q3 '25: 439.8K Q4 '25: 916.5K Q1 '26: 29.6K Q2 '26: 149.3K Q3 '26: 17K Q3 '25 Q4 '25 Q1 '26 Q2 '26 Q3 '26

Operating Cash Flow Quarterly

-24M -16M -8M 0 8M 16M 24M Q4 '21: -9M Q1 '22: -11M Q2 '22: -14.3M Q3 '22: -21.1M Q4 '22: -10.3M Q1 '23: -8.9M Q2 '23: -8.1M Q3 '23: -13.2M Q4 '23: -12.7M Q1 '24: -13M Q2 '24: -19.3M Q3 '24: -19.5M Q4 '24: -17M Q1 '25: -11M Q2 '25: -16.6M Q3 '25: -11.9M Q4 '25: -12.4M Q1 '26: -14.9M Q2 '26: -7.8M Q3 '26: -21M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Free Cash Flow Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '15: -13.5M Q4 '15: -14.3M Q1 '16: -12.4M Q2 '16: -7.1M Q3 '16: -16.5M Q4 '16: -10.7M Q1 '17: -6M Q2 '17: -4.2M Q3 '17: -5.7M Q4 '17: 55.9K Q1 '18: -9.7M Q2 '18: -7.7M Q3 '18: -8.7M Q4 '18: -9.7M Q1 '19: -10M Q2 '19: -6.3M Q3 '19: -10.5M Q4 '19: -5.9M Q1 '16 Q4 '16 Q3 '17 Q2 '18 Q1 '19 Q4 '19

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 80M 160M 240M Q3 '18: 34.5M Q3 '20: 90.8M Q1 '21: 121.7M Q2 '21: 150.7M Q3 '21: 168.4M Q1 '22: 188.2M Q2 '22: 219.1M Q3 '22: 220.5M Q1 '23: 227.4M Q2 '23: 12.8M Q3 '23: 12.8M Q1 '24: 13M Q2 '24: 14.3M Q3 '24: 25.5M Q1 '25: 24.2M Q2 '25: 30.9M Q3 '25: 37M Q1 '26: 60.2M Q2 '26: 81.8M Q3 '26: 136.7M Q3 '20 Q3 '21 Q3 '22 Q3 '23 Q3 '24 Q3 '25 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-12.00 -8.00 -4.00 0.00 4.00 8.00 12.00 Q4 '20: -0.99 Q1 '21: -0.49 Q2 '21: -0.22 Q3 '21: -0.26 Q4 '21: -0.36 Q1 '22: -0.32 Q2 '22: -0.32 Q3 '22: -0.33 Q4 '22: -0.31 Q1 '23: -0.31 Q2 '23: -0.74 Q3 '23: -2.27 Q4 '23: -3.20 Q1 '24: -3.98 Q2 '24: -11.47 Q3 '24: -10.75 Q4 '25: -1.52 Q1 '26: -2.62 Q2 '26: -1.17 Q3 '26: -0.77 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '25 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.